Kronos Bio To Present Data At ACR Convergence 2024 To Support p300 KAT Inhibition As An Approach To Anti-Inflammatory Therapy
Portfolio Pulse from Benzinga Newsdesk
Kronos Bio, Inc. (NASDAQ:KRON) will present preclinical data on its p300 KAT inhibitor program at the ACR Convergence 2024, highlighting its potential as an anti-inflammatory therapy. The presentation will occur on November 18, 2024, and the company aims to announce a development candidate for autoimmune diseases by the end of 2024.
September 25, 2024 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Kronos Bio is set to present promising preclinical data on its p300 KAT inhibitor at ACR Convergence 2024, which could position the company as a key player in anti-inflammatory therapies. The announcement of a development candidate by year-end could further boost investor confidence.
The presentation of preclinical data at a major conference like ACR Convergence 2024 is a significant event for Kronos Bio, as it highlights the potential of their p300 KAT inhibitor in treating autoimmune diseases. This could lead to increased interest and investment in the company, especially with the anticipated announcement of a development candidate by the end of 2024.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100